All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

clotiapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
psychoactive	717	2058-52-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clothiapine clothiapin clotiapine entumine	Molecular weight: 343.87 Formula: C18H18ClN3S CLOGP: 4.28 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 18.84 ALOGS: -4.38 ROTB: 0

Drug dosage:

Dose	Unit	Route
80	mg	O
80	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.858		Moderate	0.77
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.497		Moderate	0.77
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	28.510	10^-6 cm/s	Moderate	0.77
dh-clint	Dog hepatocyte intrinsic clearance	45.290	uL/min/10^6 cells	Moderate	0.77
dppb	Dog plasma protein binding (% unbound)	1.440	%	Moderate	0.77
fcs-ppb	Fetal calf serum protein binding (% unbound)	4.680	%	Moderate	0.77
herg	hERG pIC50	5.628	pIC50	Moderate	0.77
hh-clint	Human hepatocyte intrinsic clearance	10.789	uL/min/10^6 cells	Moderate	0.77
hlm-clint	Human liver microsomal intrinsic clearance	29.854	uL/min/mg protein	Moderate	0.77
hppb	Human plasma protein binding (% unbound)	1.480	%	Moderate	0.77
kinase-safety-class	ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,PDK2,PDK4,PRKDC	12
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.384		Moderate	0.77
mh-clint	Mouse hepatocyte intrinsic clearance	113.240		Moderate	0.77
mppb	Mouse plasma protein binding (% unbound)	2.560		Moderate	0.77
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.225		Moderate	0.77
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	4.370	%	Moderate	0.77
rh-clint	Rat hepatocyte intrinsic clearance	229.615	uL/min/10^6 cells	Moderate	0.77
rh-fuinc	Rat hepatocyte fraction unbound in incubation	11.930	%	Moderate	0.77
rppb	Rat plasma protein binding (% unbound)	2.040	%	Moderate	0.77
solubility-dd	Solubility at pH 7.4 in DMSO	10.691	uM	Moderate	0.77

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	260.64	86.73	71	703	82276	90545397
Sopor	258.96	86.73	56	718	24588	90603085
Intentional overdose	122.20	86.73	41	733	93793	90533880
Coma	107.55	86.73	35	739	72597	90555076

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	217.96	59.48	53	1010	13149	42607123
Drug abuse	125.88	59.48	58	1005	104713	42515559
Sudden death	86.50	59.48	27	1036	16602	42603670
Toxicity to various agents	81.08	59.48	57	1006	229079	42391193

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	455.81	56.28	109	1809	36437	110550944
Drug abuse	356.44	56.28	128	1790	177283	110410098
Toxicity to various agents	127.04	56.28	87	1831	480468	110106913
Intentional self-injury	121.77	56.28	39	1879	37390	110549991
Intentional overdose	113.15	56.28	52	1866	132449	110454932
Depressed level of consciousness	111.57	56.28	49	1869	112229	110475152
Suicide attempt	108.84	56.28	47	1871	103347	110484034
Coma	87.42	56.28	42	1876	117827	110469554
Sudden death	85.82	56.28	27	1891	24368	110563013
Neuroleptic malignant syndrome	65.64	56.28	24	1894	34035	110553346

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AH06	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
MeSH PA	D014150	Antipsychotic Agents
CHEBI has role	CHEBI:35476	antipsychotic agent

Related Drugs by ATC class:

N05AH Diazepines, oxazepines, thiazepines and oxepines 6 drugs

asenapineclozapineloxapineolanzapinequetiapinesamidorphan

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.59	Basic
pKa2	3.09	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	9.31		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.36		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	7.85		CHEMBL
Muscarinic acetylcholine receptor	GPCR		ACM1_RAT ACM3_RAT ACM4_RAT ACM5_RAT ACM2_RAT		Ki	6.87		CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	9.23		CHEMBL

External reference:

ID	Source
D01597	KEGG_DRUG
2620	RXNORM
C0009071	UMLSCUI
CHEBI:31424	CHEBI
CHEMBL304902	ChEMBL_ID
DB13256	DRUGBANK_ID
C084602	MESH_SUPPLEMENTAL_RECORD_UI
16351	PUBCHEM_CID
006953	NDDF
698028004	SNOMEDCT_US
2136	INN_ID
Z05HCY0X1T	UNII

Pharmaceutical products:

None